Restatement of Previously Issued Condensed Consolidated Statement of Cashflows (Details) - USD ($)
$ in Thousands |
3 Months Ended |
6 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2024 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Sep. 30, 2023 |
Jun. 30, 2023 |
Mar. 31, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Dec. 31, 2024 |
Dec. 31, 2023 |
| Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Net income |
$ 1,676
|
$ 2,437
|
$ 708
|
$ (186)
|
$ 559
|
$ 514
|
$ 3,145
|
$ 1,073
|
$ 4,821
|
$ 887
|
$ 6,702
|
$ 1,954
|
| Adjustments to reconcile net income to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
300
|
1,026
|
| Interest accretion expense |
|
|
19
|
|
|
35
|
30
|
66
|
34
|
92
|
34
|
112
|
| Amortization of deferred financing fees |
|
|
|
|
|
14
|
|
28
|
|
42
|
|
42
|
| Amortization on operating lease right of use asset |
|
|
108
|
|
|
|
229
|
|
332
|
|
448
|
575
|
| Stock-based compensation |
|
|
79
|
|
|
192
|
132
|
349
|
218
|
501
|
291
|
630
|
| Credit loss expense |
|
|
26
|
|
|
|
26
|
|
26
|
|
|
|
| Change in fair value of note payable |
|
|
98
|
|
|
(33)
|
41
|
142
|
445
|
400
|
547
|
678
|
| Change in fair value of contingent consideration |
|
|
|
|
|
|
|
|
|
|
|
7
|
| Other changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts receivable |
|
|
46
|
|
|
488
|
(1,154)
|
(345)
|
(2,241)
|
229
|
(3,466)
|
227
|
| Other current assets |
|
|
343
|
|
|
107
|
|
(101)
|
237
|
176
|
73
|
(89)
|
| Accounts payable |
|
|
(176)
|
|
|
532
|
(13)
|
610
|
137
|
228
|
120
|
489
|
| Accrued salaries and bonus |
|
|
(1,091)
|
|
|
(568)
|
(726)
|
(329)
|
(320)
|
(157)
|
238
|
513
|
| Other accrued expenses |
|
|
(159)
|
|
|
(583)
|
(373)
|
(837)
|
(236)
|
(1,120)
|
|
(2,266)
|
| Operating lease liabilities |
|
|
(115)
|
|
|
|
(188)
|
(337)
|
(355)
|
(292)
|
(480)
|
(376)
|
| Long-term liabilities |
|
|
104
|
|
|
79
|
178
|
162
|
259
|
248
|
243
|
267
|
| Net cash provided by operating activities |
|
|
(58)
|
|
|
1,133
|
1,346
|
1,544
|
3,462
|
2,649
|
4,646
|
3,789
|
| Cash Flows From Investing Activity |
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from sale of Interpace Pharma Solutions, net |
|
|
|
|
|
|
|
117
|
|
117
|
|
383
|
| Purchase of property and equipment |
|
|
(28)
|
|
|
(65)
|
(225)
|
(176)
|
(747)
|
(328)
|
(876)
|
(470)
|
| Net cash used in investing activities |
|
|
(28)
|
|
|
(65)
|
(225)
|
(293)
|
(747)
|
55
|
(876)
|
(87)
|
| Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Payment of BroadOak terminal payment |
|
|
|
|
|
|
|
|
|
|
|
(2,500)
|
| Payments on line of credit |
|
|
|
|
|
(300)
|
|
(1,000)
|
|
(2,500)
|
|
(2,500)
|
| Cash paid for repurchase of restricted shares |
|
|
|
|
|
|
|
|
|
|
(46)
|
(32)
|
| Net cash used in financing activities |
|
|
(600)
|
|
|
(300)
|
(2,600)
|
(1,000)
|
(4,100)
|
(2,500)
|
(5,807)
|
(5,032)
|
| Net decrease in cash and cash equivalents |
|
|
(686)
|
|
|
768
|
(1,479)
|
251
|
(1,385)
|
204
|
(2,037)
|
(1,330)
|
| Cash and cash equivalents from continuing operations – beginning |
|
|
3,498
|
|
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
| Cash and cash equivalents from discontinued operations – beginning |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents – beginning |
2,019
|
2,812
|
3,498
|
5,079
|
5,596
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
| Cash and cash equivalents from continuing operations – ending |
|
|
|
|
|
|
|
|
|
|
1,461
|
3,498
|
| Cash and cash equivalents from discontinued operations – ending |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents – ending |
2,113
|
2,019
|
2,812
|
5,032
|
5,079
|
5,596
|
2,019
|
5,079
|
2,113
|
5,032
|
1,461
|
3,498
|
| Previously Reported [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Net income |
1,280
|
2,062
|
468
|
(614)
|
175
|
351
|
2,530
|
526
|
3,810
|
(88)
|
|
802
|
| Adjustments to reconcile net income to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
1,026
|
| Interest accretion expense |
|
|
19
|
|
|
35
|
30
|
66
|
34
|
92
|
|
112
|
| Amortization of deferred financing fees |
|
|
|
|
|
14
|
|
28
|
|
42
|
|
42
|
| Amortization on operating lease right of use asset |
|
|
108
|
|
|
|
229
|
|
332
|
|
|
575
|
| Stock-based compensation |
|
|
79
|
|
|
192
|
132
|
349
|
218
|
501
|
|
630
|
| Credit loss expense |
|
|
26
|
|
|
|
26
|
|
26
|
|
|
|
| Change in fair value of note payable |
|
|
98
|
|
|
(33)
|
41
|
142
|
445
|
400
|
|
678
|
| Change in fair value of contingent consideration |
|
|
|
|
|
|
|
|
|
|
|
7
|
| Other changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts receivable |
|
|
(49)
|
|
|
317
|
(1,249)
|
(497)
|
(2,336)
|
202
|
|
49
|
| Other current assets |
|
|
343
|
|
|
107
|
|
(101)
|
237
|
176
|
|
(89)
|
| Accounts payable |
|
|
(176)
|
|
|
532
|
(13)
|
610
|
137
|
228
|
|
489
|
| Accrued salaries and bonus |
|
|
(1,091)
|
|
|
(568)
|
(726)
|
(329)
|
(320)
|
(157)
|
|
513
|
| Other accrued expenses |
|
|
176
|
|
|
(249)
|
337
|
(138)
|
870
|
(118)
|
|
(936)
|
| Operating lease liabilities |
|
|
(115)
|
|
|
|
(188)
|
(337)
|
(355)
|
(292)
|
|
(376)
|
| Long-term liabilities |
|
|
104
|
|
|
79
|
178
|
162
|
259
|
248
|
|
267
|
| Net cash provided by operating activities |
|
|
(58)
|
|
|
1,133
|
1,346
|
1,544
|
3,462
|
2,649
|
|
3,789
|
| Cash Flows From Investing Activity |
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from sale of Interpace Pharma Solutions, net |
|
|
|
|
|
|
|
117
|
|
117
|
|
383
|
| Purchase of property and equipment |
|
|
(28)
|
|
|
(65)
|
(225)
|
(176)
|
(747)
|
(328)
|
|
(470)
|
| Net cash used in investing activities |
|
|
(28)
|
|
|
(65)
|
(225)
|
(293)
|
(747)
|
55
|
|
(87)
|
| Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Payment of BroadOak terminal payment |
|
|
|
|
|
|
|
|
|
|
|
(2,500)
|
| Payments on line of credit |
|
|
|
|
|
(300)
|
|
(1,000)
|
|
(2,500)
|
|
(2,500)
|
| Cash paid for repurchase of restricted shares |
|
|
|
|
|
|
|
|
|
|
|
(32)
|
| Net cash used in financing activities |
|
|
(600)
|
|
|
(300)
|
(2,600)
|
(1,000)
|
(4,100)
|
(2,500)
|
|
(5,032)
|
| Net decrease in cash and cash equivalents |
|
|
(686)
|
|
|
768
|
(1,479)
|
251
|
(1,385)
|
204
|
|
(1,330)
|
| Cash and cash equivalents from continuing operations – beginning |
|
|
3,498
|
|
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
| Cash and cash equivalents from discontinued operations – beginning |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents – beginning |
2,019
|
2,812
|
3,498
|
5,079
|
5,596
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
3,498
|
4,828
|
| Cash and cash equivalents from continuing operations – ending |
|
|
|
|
|
|
|
|
|
|
|
3,498
|
| Cash and cash equivalents from discontinued operations – ending |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents – ending |
2,113
|
2,019
|
2,812
|
5,032
|
5,079
|
5,596
|
2,019
|
5,079
|
2,113
|
5,032
|
|
3,498
|
| Revision of Prior Period, Reclassification, Adjustment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Net income |
396
|
375
|
240
|
428
|
384
|
163
|
615
|
547
|
1,011
|
975
|
|
1,152
|
| Adjustments to reconcile net income to net cash used in operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
|
| Interest accretion expense |
|
|
|
|
|
|
|
|
|
|
|
|
| Amortization of deferred financing fees |
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
| Credit loss expense |
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of note payable |
|
|
|
|
|
|
|
|
|
|
|
|
| Change in fair value of contingent consideration |
|
|
|
|
|
|
|
|
|
|
|
|
| Other changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts receivable |
|
|
95
|
|
|
171
|
95
|
152
|
95
|
27
|
|
178
|
| Other current assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts payable |
|
|
|
|
|
|
|
|
|
|
|
|
| Accrued salaries and bonus |
|
|
|
|
|
|
|
|
|
|
|
|
| Other accrued expenses |
|
|
(335)
|
|
|
(334)
|
(710)
|
(699)
|
(1,106)
|
(1,002)
|
|
(1,330)
|
| Long-term liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash provided by operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Flows From Investing Activity |
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from sale of Interpace Pharma Solutions, net |
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase of property and equipment |
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash used in investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Payments on line of credit |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash paid for repurchase of restricted shares |
|
|
|
|
|
|
|
|
|
|
|
|
| Net cash used in financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
| Net decrease in cash and cash equivalents |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents from continuing operations – beginning |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents from discontinued operations – beginning |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents – beginning |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents from continuing operations – ending |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents from discontinued operations – ending |
|
|
|
|
|
|
|
|
|
|
|
|
| Cash and cash equivalents – ending |
|
|
|
|
|
|
|
|
|
|
|
|